Filtered By:
Specialty: International Medicine & Public Health
Drug: Warfarin
This page shows you your search results in order of date.
Order by Relevance | Date
Total 58 results found since Jan 2013.
MT45 Cost-Effectiveness Analysis of Left Atrial Appendage Closure (LAAC) Device Vesus Warfarin and New Oral Anticoagulants (NOACS) in Patients with Atrial Fibrillation (AF) - Large Brazilian Healthcare Payer Perspective
The objective of the study was to evaluate the cost-effectiveness of LAAC with WATCHMAN device in the perspective of a large Brazilian healthcare payer with more than 18 million patients.
Source: Value in Health - June 1, 2023 Category: International Medicine & Public Health Authors: H. Tortele, S. Rodrigues, Cont ó M Source Type: research
CO4 Outcomes of Non –Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Diabetes Mellitus: A Systematic Review of Randomized Controlled Trials and Observational Studies
This study aimed to ident ify differences between original studies of NOACs vs warfarin to support interpretation of results across studies.
Source: Value in Health - June 1, 2023 Category: International Medicine & Public Health Authors: R. Wang, H. Lien, A. Borrow, D. Fleishman Source Type: research
EE340 Integrating Real-World Evidence in Economic Evaluation of Oral Anticoagulants for Stroke Prevention in Non-Valvular Atrial Fibrillation in a Developing Country
This study assessed the cost-effectiveness of DOACs compared to warfarin with varying anticoagulation controls for stroke prevention in NVAF patients in real-world setting in Thailand.
Source: Value in Health - June 1, 2023 Category: International Medicine & Public Health Authors: M.S. Syeed, T. Nonthasawadsri, R.E. Nelson, N. Chaiyakunapruk, S. Nathisuwan Source Type: research
Oral anticoagulants: a systematic overview of reviews on efficacy and safety, genotyping, self-monitoring, and stakeholder experiences
ConclusionsFor stroke prevention in AF, direct OACs seem to be more effective and safer than usual care, and apixaban (5 mg twice daily) had the best profile. For VTE, there was no strong evidence that direct OACs were better than usual care. Education and pharmacist management could improve coagulation control. Both clinicians and patients rated efficacy and safety as the most important factors in managing AF and V TE.Systematic review registrationPROSPERO CRD42017084263 —one deviation; efficacy and safety were from one review.
Source: Systematic Reviews - October 28, 2022 Category: International Medicine & Public Health Source Type: research
CO55 Efficacy and Safety of Direct Oral Anticoagulants (DOACS) Versus Warfarin in Atrial Fibrillation Patients with Prior Stroke: A Systematic Review and Meta-Analysis
The purpose of this meta-analysis was to compare efficacy and safety of direct oral anticoagulants (DOACs) to warfarin for secondary stroke prevention among adult patients with atrial fibrillation and prior stroke.
Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: K Umashankar, M Mammi, E Badawoud, Y Tang, M Zhou, JC Borges, A Liew, M Migliore, RA Mekary Source Type: research
P73 Real-World Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants (NOAC) in Patients with Non-Valvular Atrial Fibrillation (NVAF): A Retrospective Cohort Study in Singapore
This study aims to compare the real-world effectiveness and safety between NOAC and warfarin in NVAF patients and assess the potential long-term impact on the healthcare system in Singapore.
Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: W. Foo, T. Hui, S.K.B. Ong, K.H. Ng Tags: Real-World Evidence for Comparative Effectiveness, Safety and Adherence Evaluations Source Type: research
EE411 Healthcare Costs of Direct Oral Anticoagulants Among Medicare Patients with Nonvalvular Atrial Fibrillation and Multimorbidity
To evaluate cost differences between stroke/systemic embolism (S/SE) and major bleeding (MB) among nonvalvular atrial fibrillation (NVAF) patients with multimorbidity prescribed direct oral anticoagulants (DOACs) or warfarin.
Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: AD Dhamane, M Ferri, A Keshishian, C Russ, N Atreja, R Thomas, G Leung, B Emir, H Yuce, M DiFusco Source Type: research
The prevalence of atrial fibrillation in Greenland: a register-based cross-sectional study based on disease classifications and prescriptions of oral anticoagulants
This study estimates the prevalence of AF based on disease classifications in the electronic medical record system (EMR) and prescriptions of oral anticoagulants (OACs). Patients given a diagnose classification code for AF or atrial flutter or prescribed the vitamin K antagonist Warfarin or the direct-acting oral anticoagulant Rivaroxaban were identified in the EMR. Descriptive data and selected laboratory values were extracted, and a minimum CHA2DS2-VASc score was calculated for the 790 patients identified in the EMR (66% men). A total prevalence of AF of 1.4% was found in the general population (1.8% among men and 1.0% a...
Source: International Journal of Circumpolar Health - January 28, 2022 Category: International Medicine & Public Health Authors: N Albertsen S Riahi M L Pedersen N Skovgaard S Andersen Source Type: research
PCV57 Persistence to Warfarin Among Patients with Atrial Fibrillation and Comorbid Hypertension, Diabetes and Hyperlipidemia
The objective of this study was to examine the persistence to Warfarin and to evaluate the predictors associated with non-persistence to Warfarin among patients with comorbid AF, diabetes, hypertension, and hyperlipidemia.
Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: A. Mohan, Z. Majd, R. Paranjpe, A. Vadhariya, O. Serna, S.M. Abughosh Source Type: research
Secondary analysis confirms safety of blood thinning agent
(American Heart Association) The blood thinner apixaban, which treats and prevents blood clots in some people with irregular heart rhythm, is safe and effective in stroke patients. Apixaban is associated with less bleeding, death and hospitalization than warfarin.
Source: EurekAlert! - Medicine and Health - February 21, 2020 Category: International Medicine & Public Health Source Type: news
Optimal Choice of Pharmacological Therapy – Prevention of Stroke and Assessment of Bleeding Risk in Patients with Atrial Fibrillation
Conclusions:Novel oral anticoagulants (NOACs) seem to be a better choice as a pharmacological therapy in the treatment of AF, due to a lack of adequate monitoring of patients ’ international normalized ratio (INR) values. CHA2DS2‑VASc and HASBLED scores must be used as a part of routine clinical diagnostics when dealing with patients with AF.Keywords:Atrial fbrillation, hemorrhage, risk, stroke, therapeutics
Source: International Journal of Preventive Medicine - June 3, 2019 Category: International Medicine & Public Health Source Type: research
Barriers to using stroke-preventing anticoagulants in Canada hinder appropriate management of patients with atrial fibrillation
(Elsevier) International guidelines recommend direct oral anticoagulants (DOACs) over warfarin to prevent stroke for most patients with atrial fibrillation (AF). However, a substantial portion of patients in Canada, who would benefit from anticoagulation, do not receive it adequately or at all. Experts review the evidence for the use of DOACs in the Canadian Journal of Cardiology, discuss reasons for the large gap between guidelines and clinical practice, including policy and funding barriers, and propose strategies for the future.
Source: EurekAlert! - Medicine and Health - November 5, 2018 Category: International Medicine & Public Health Source Type: news
Cost-Utility Analysis of Apixaban versus Warfarin in Atrial Fibrillation Patients with Chronic Kidney Disease
Warfarin use for stroke prevention in atrial fibrillation (AF) patients with chronic kidney disease is debated. Apixaban was shown to be safer than warfarin, with superior reduction in the risk of stroke, systemic embolism, mortality, and major bleeding irrespective of kidney function.
Source: Value in Health - July 24, 2018 Category: International Medicine & Public Health Authors: Shoroq M. Altawalbeh, Osama Y. Alshogran, Kenneth J. Smith Source Type: research
